Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIVTENCITY all-case post-marketing surveillance in refractory CMV infection after transplantation
jRCT2031240302Recruiting
- Sponsor
- Takeda
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of maribavir in cytomegalovirus disease (CMV), sponsored by Takeda. Primary endpoint: Number of participants who experience at least one adverse drug reaction. Started Aug 2024; status: recruiting.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT2031240302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240302.